Idrx
About Idrx
IDRx is developing IDRX-42, an oral KIT tyrosine kinase inhibitor targeting specific mutations in gastrointestinal stromal tumors (GIST) to enhance treatment efficacy. The company addresses the significant unmet medical need for effective therapies in GIST, where current standards of care have remained unchanged for nearly two decades.
<problem> Gastrointestinal stromal tumors (GIST) driven by KIT mutations often develop resistance to existing tyrosine kinase inhibitors (TKIs), and current standards of care have remained largely unchanged for two decades, creating a significant unmet need for more effective therapies. </problem> <solution> IDRx is developing IDRX-42, an oral, small molecule KIT TKI designed to selectively target prevalent KIT mutations that drive initial tumor growth or confer resistance to currently available therapies in GIST. IDRX-42 aims to improve outcomes for patients with GIST as a first- or second-line therapy. The company is currently evaluating IDRX-42 in an open-label Phase 1/1b clinical trial (StrateGIST 1) for advanced GIST and plans to initiate StrateGIST 3, a global, randomized, open-label Phase 3 registrational trial, to evaluate IDRX-42 as a second-line therapy. </solution> <features> - Oral small molecule KIT tyrosine kinase inhibitor (TKI) - Designed to selectively target prevalent KIT mutations in GIST - Clinical development as a monotherapy for GIST - Being evaluated in Phase 1/1b clinical trial (StrateGIST 1) for advanced GIST - Planned Phase 3 registrational trial (StrateGIST 3) as a second-line therapy </features> <target_audience> The primary target audience includes patients with gastrointestinal stromal tumors (GIST) who have developed resistance to existing therapies or require first-line treatment, and the oncologists who treat them. </target_audience>
What does Idrx do?
IDRx is developing IDRX-42, an oral KIT tyrosine kinase inhibitor targeting specific mutations in gastrointestinal stromal tumors (GIST) to enhance treatment efficacy. The company addresses the significant unmet medical need for effective therapies in GIST, where current standards of care have remained unchanged for nearly two decades.
Where is Idrx located?
Idrx is based in Plymouth, United Kingdom.
When was Idrx founded?
Idrx was founded in 2022.
How much funding has Idrx raised?
Idrx has raised 242000000.
Who founded Idrx?
Idrx was founded by Tim Clackson.
- Tim Clackson - CEO
- Location
- Plymouth, United Kingdom
- Founded
- 2022
- Funding
- 242000000
- Employees
- 43 employees
- Major Investors
- Blackstone Group, RA Capital Management